Hyaluronidase / rituximab
RxNorm 1927884

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1927884 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: hyaluronidase / rituximab.

The following semantic concepts and normalized strings are associated with this clinical entity:

MIN
Hyaluronidase / rituximab
AUI:12352810
TMSY
Hyaluronidase / riTUXimab
AUI:12378481

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

MINPrescribable

Multiple Ingredients (MIN):
Hyaluronidase / rituximab
(Atom ID: 12352810)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
hyaluronidase / rituximab
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1927884
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12352810
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
MIN
Multiple Ingredients (Two or more ingredients appearing together in a single drug preparation, created from SCDF. In rare cases when IN/PIN or PIN/PIN combinations of the same base ingredient exist, created from SCD.)
Source Code
1927884
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

TMSYPrescribable

Tall Man Lettering Synonym (TMSY):
Hyaluronidase / riTUXimab
(Atom ID: 12378481)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
hyaluronidase / riTUXimab
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1927884
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12378481
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
1927884
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Rituximab and Hyaluronidase Human Injection


Rituximab and hyaluronidase human injection is used alone or with other medications to treat various types of non-Hodgkin's lymphoma (NHL; a type of cancer that begins in a type of white blood cells that normally fights infection). Rituximab and hyaluronidase human injection is also used with other medications to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Rituximab and hyaluronidase human injection is in a class of medications called monoclonal antibodies. It treats the various types of NHL and CLL by killing cancer cells.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.